Revenue Breakdown
Composition ()
No data
Revenue Streams
Collegium Pharmaceutical Inc (COLL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Nucynta IR, accounting for 43.1% of total sales, equivalent to $90.24M. Other significant revenue streams include Belbuca and Xtampza ER. Understanding this composition is critical for investors evaluating how COLL navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Collegium Pharmaceutical Inc maintains a gross margin of 61.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 31.85%, while the net margin is 15.05%. These profitability ratios, combined with a Return on Equity (ROE) of 22.96%, provide a clear picture of how effectively COLL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, COLL competes directly with industry leaders such as INVA and OCS. With a market capitalization of $1.43B, it holds a significant position in the sector. When comparing efficiency, COLL's gross margin of 61.70% stands against INVA's 70.07% and OCS's N/A. Such benchmarking helps identify whether Collegium Pharmaceutical Inc is trading at a premium or discount relative to its financial performance.
